← Search

Omics · study · 2026

REV-ERBs agonist SR9009 inhibits liver fibrosis progression in a MASH fibrosis model invivo.

Listed in NCBI GEO

To explore the CC as a therapeutic target for MASH-induced fibrosis, we studied whether SR9009, a pharmacological activator of REV-ERBα, modulates fibrosis in CDA-HFD fed C57Bl/6J mice, a state-of-the-art model for MASH fibrosis

Links

Topics

From keywords
Life Sciences
Provenance · 1 source records, 7 field assertions
SourceKeyLast seenRaw
NCBI GEOGSE27229315 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[field].local:field:life-sciencesmapping · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencingsource · NCBI GEOconnector:ncbi_geo@1.0.0/gdstype
concepts[organism].NCBITaxon:10090source · NCBI GEOconnector:ncbi_geo@1.0.0/taxon
descriptionsource · NCBI GEOconnector:ncbi_geo@1.0.0/summary
publication_datesource · NCBI GEOconnector:ncbi_geo@1.0.0
titlesource · NCBI GEOconnector:ncbi_geo@1.0.0/title